Monday, October 26, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· February 28, 2026

Pebblebrook Hotel Trust Q4 Earnings Call Highlights

View original at finance.yahoo.com
Pebblebrook Hotel Trust Q4 Earnings Call Highlights Pebblebrook Hotel Trust logo Key Points Q4 results beat expectations: Same-property total RevPAR rose 2.9% and adjusted EBITDA increased 11.1% to $69.7 million, with adjusted EPS of $0.27, helped by stronger occupancy (+190 bps) and a 5.5% gain in non-room RevPAR…
Opening lines of the source · Yahoo Finance · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The lower capital run rate is a tailwind that could support higher discretionary free cash flow for debt paydowns and repurchases

    80% confidence
  • Pebblebrook ended 2025 with stronger than expected fourth-quarter growth even as the government shutdown weighed on demand

    80% confidence
  • San Francisco RevPAR increased 37.9% in the quarter

    80% confidence
  • Most of the company's pace advantage was in transient demand, while group room nights were down 0.6% for the year

    80% confidence
  • January RevPAR increased 4.6% and would have been almost 7% but for Winter Storm Fern

    80% confidence
  • In December when there were zero conventions, Pebblebrook's San Francisco portfolio still delivered 16.2% RevPAR growth

    80% confidence
  • February was on pace for RevPAR growth of 15%+

    80% confidence
  • Weighted average interest cost of 4.1% is the lowest in the hotel lodging REIT sector

    80% confidence
  • Same-property hotel EBITDA was $2.2 million above the midpoint of the company's outlook

    80% confidence
  • Results reflected benefits from Pebblebrook's multi-year strategic reinvestment program and that several redeveloped properties are still ramping toward stabilization

    80% confidence
  • Pebblebrook may be reaching a favorable transition point

    80% confidence
  • Fourth-quarter total RevPAR in San Francisco increased more than 32%

    80% confidence
  • 2025 featured two very different storylines, with redeveloped resorts and urban recovery markets—especially San Francisco—driving growth, while Los Angeles and Washington, D.C. weighed on results due to unexpected events

    80% confidence
  • The company continued to see softness in government and government-related segments

    80% confidence
  • Full-year same-property expenses rose 3%, and excluding real estate tax and other credits from the prior year, total expense growth was 2.2%, with cost per occupied room basically flat

    80% confidence
  • The company does not expect additional business interruption income in 2026 for LaPlaya

    80% confidence
  • The company refinanced near-term maturities, extended maturities, increased the unencumbered asset base, and provided a fully funded path to address $350 million of convertible notes due December 2026

    80% confidence
  • Adjusted EBITDA was about $6 million above the midpoint

    80% confidence
  • Weather resiliency improvements at LaPlaya are complete and the property is fully restored following Hurricanes Helene and Milton

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com